Every material Form 8-K Benitec Biopharma Inc. has filed with the SEC since September 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Benitec Biopharma announced positive interim Phase 1b/2a clinical results for high dose BB-301 and continued durable improvements for low dose BB-301 in patients with oculopharyngeal muscular dystrophy (OPMD). The company reports a 100% responder rate across all patients treated to date and no serious adverse events, but the filing contains clinical data only, with no financial results, and the company cautions that interim results may not be maintained.
All six Cohort 1 (low dose) patients and all three Cohort 2 (high dose) patients are formal responders to BB-301.
At 3 months, 100% of Cohort 2 patients met the statistical criteria for improved throat emptying ability, versus 67% of Cohort 1 patients.
No serious adverse events have been reported in any patient treated with BB-301 to date.
The company plans a pivotal study of BB-301 in mid-2027.
Benitec Biopharma said the FDA asked for additional available data, including from the company-sponsored OPMD Natural History Study, as discussions on an open-label, single-arm pivotal study for BB-301 continue. The company said it expects to confirm the final pivotal design in the first quarter of 2027 and that the pivotal study timeline remains on track, with patient enrollment planned to begin in mid-2027.
FDA requested additional available data, including from the Benitec-sponsored OPMD Natural History Study
Final pivotal study design expected to be confirmed in 1Q 2027
Patient enrollment for the BB-301 pivotal study planned to begin in mid-2027
Interim BB-301 Phase 1b/2a results to be presented as a late-breaking poster at ESGCT in Hamburg, October 27-30, 2026
Benitec Biopharma disclosed that Ernst & Young LLP (EY) has been engaged as its independent registered public accounting firm for the fiscal year ending June 30, 2027, after EY completed its client acceptance procedures on September 28, 2026. The company and EY signed an engagement letter on September 29, 2026. The filing is an administrative update on the company's auditor and does not report financial results or a disagreement with the prior accountant.
EY completed client acceptance procedures on September 28, 2026.
The Company and EY executed an engagement letter on September 29, 2026.
EY is engaged for the fiscal year ending June 30, 2027.
The engagement was first reported in a Form 8-K filed September 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Benitec Biopharma Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →